RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Manufacturing facilities are located in Little Elm, Texas, with significant outsourcing to a Chinese manufacturer (Double Dove). Safety syringes comprised 98.5% of sales for the nine months ended September 30, 2010.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.8% for the three months and 29.3% for the nine months ended September 30, 2010, compared to the prior year periods. Domestic revenues increased due to higher average sales prices, while international revenues grew due to higher volumes.
• Profitability Turnaround: The Company reported a net income of $8.2 million for the quarter, compared to a net loss of $3.4 million in the same period last year. This is primarily driven by a $7.3 million litigation settlement gain.
• Operating Expenses: Total operating expenses decreased 35.5% for the quarter and 7.1% for the nine months, attributed to lower litigation costs (due to a capped fee agreement) and reduced salary levels from prior cost-cutting measures.
• Inventory Build-up: Inventories increased 45.6% year-over-year to $10.1 million, largely due to preparation for the flu season.
• Debt Reduction: Total liabilities decreased significantly from $18.0 million to $10.8 million, driven by the payoff of a $2.1 million warehouse loan and the waiver of marketing fees.

Guidance, Outlook, and Risks

• Litigation Settlements: A significant portion of current period income ($7.3 million) stems from a settlement with Abbott Laboratories and Hospira. Hospira paid $6 million and Abbott waived a $1.4 million marketing fee and $144,000 invoice. Hospira also received an exclusive option to license the Patient Safe syringe, with potential future payments of $8 million.
• Legal Proceedings: Becton Dickinson (BD) has appealed a $5 million judgment in favor of the Company regarding patent infringement. The permanent injunction against BD's products is stayed pending the appeal, expected to conclude in 2011. The Company also has an active antitrust suit against BD.
• Supply Chain Concentration: Approximately 64.9% of finished products were sourced from Double Dove in China. Disruption here could impact supply of specific syringe types, though the Company plans to increase domestic production if necessary.
• Liquidity: The Company maintains strong liquidity with cash comprising 39.1% of total assets. Management expects to fund operations through cash reserves, operating cash flow, and existing debt facilities.
• Preferred Stock Dividends: Significant dividends remain in arrears on Series III, IV, and V Class B Preferred Stock, though the Abbott settlement reduced the arrearage on Series IV.

Investor Verification Checklist

• Sustainability of Earnings: Verify the extent to which the $8.2 million quarterly net income is driven by the non-recurring $7.3 million litigation settlement versus core operational performance.
• BD Litigation Outcome: Monitor the appeal of the $5 million judgment against Becton Dickinson, as a reversal could impact future revenue and legal costs.
• Supply Chain Resilience: Assess the risk associated with relying on a single Chinese manufacturer (Double Dove) for nearly 65% of finished goods.
• Preferred Stock Obligations: Review the total dividend arrearages on Class B Preferred Stock and the impact of the Abbott waiver on future cash flow requirements.
• Inventory Levels: Evaluate the $10.1 million inventory balance against sales velocity to ensure no significant write-downs are required post-flu season.